Last Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Juta Pharma’s pegfilgrastim biosimilar, Grasustek.
Last Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Juta Pharma’s pegfilgrastim biosimilar, Grasustek.
The next step for the biosimilar will be to await the European Commission (EC)’s final decision on whether to grant a marketing approval for the biosimilar. If the EC ultimately approves the product, it will grant the company a centralized marketing authorization that will be valid in all 28 EU member states. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will follow with corresponding decisions based on the EC’s decision.
If authorized, Grasustek will be available as a 6 mg solution for injection for the prophylaxis of neutropenia in adults being treated with cytotoxic chemotherapy.
The pegfilgrastim biosimilar was developed by USV, a Mumbai-based biosimilar developer that submitted the application for the biosimilar in December 2017. USV later acquired Juta Pharma, a German drug maker with extensive experience in generic drug products.
The application for the biosimilar included data from phase 1 and phase 3 studies of the biosimilar; the phase 1 study compared the pharmacokinetics and pharmacodynamics of the biosimilar with the reference Neulasta at both a therapeutic dose and a low dose, and the phase 3 study followed 254 patients with breast cancer who were scheduled to undergo chemotherapy.
USV also disclosed that it had begun planning for US phase 1 development, and held relevant meetings with the FDA. The company also received approval to initiate phase 3 studies in India.
If Grasustek is authorized in the European Union, it will join already authorized pegfilgrastim biosimilars Fulphila, Ziextenzo, Udenyca, Pelmeg, and Pelgraz. Additional EU-marketed biosimilars used in the prophylaxis of febrile neutropenia are those referencing filgrastim, and include Zarzio (also sold as Filgrastim Hexal), Accofil, Grastofil, Nivestim, and Ratiograstim (also sold as Tevagrastim).
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.